CARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma

Reuters

2025/12/07

CARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Ltd. announced that its fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel), has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025) following approval from the National Healthcare Security Administration (NHSA). Zevor-cel received marketing authorization from the National Medical Products Administration (NMPA) on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy. This inclusion is expected to improve patient access to the therapy and reflects national support for innovative treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN40954) on December 07, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2589587181"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589587181\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589587181?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 17:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589587181","market":"nz","top_or_hot":-1,"title":"CARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings Ltd. announced that its fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel), has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025) following approval from the <a href=\"https://laohu8.com/S/NHC\">National Healthcare</a> Security Administration (NHSA). Zevor-cel received marketing authorization from the National Medical Products Administration (NMPA) on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy. This inclusion is expected to improve patient access to the therapy and reflects national support for innovative treatments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN40954) on December 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-07 17:22</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings Ltd. announced that its fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel), has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025) following approval from the <a href=\"https://laohu8.com/S/NHC\">National Healthcare</a> Security Administration (NHSA). Zevor-cel received marketing authorization from the National Medical Products Administration (NMPA) on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy. This inclusion is expected to improve patient access to the therapy and reflects national support for innovative treatments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN40954) on December 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDLy7y7N:1","article_id":"2589587181","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589587181","pubTimestamp":1765099332,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CARsgen Therapeutics Holdings Ltd. announced that its fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel , has been included in China's Commercial Health Insurance Innovative Drug Catalogue  following approval from the National Healthcare Security Administration . Zevor-cel received marketing authorization from the National Medical Products Administration  on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy. This inclusion is expected to improve patient access to the therapy and reflects national support for innovative treatments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","BK1585":"昨日强势股","NHC":"National Healthcare Corp","BK4185":"保健护理机构","02171":"科济药业-B"},"translate_title":"科济生物Zevor-Cel在中国获批用于复发/难治性多发性骨髓瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":0.9,"NHC":0.9},"content_text":"CARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma\n    \n\n        CARsgen Therapeutics Holdings Ltd. announced that its fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel), has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025) following approval from the National Healthcare Security Administration (NHSA). Zevor-cel received marketing authorization from the National Medical Products Administration (NMPA) on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy. This inclusion is expected to improve patient access to the therapy and reflects national support for innovative treatments.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN40954) on December 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}